PMID- 15656007
OWN - NLM
STAT- MEDLINE
DCOM- 20050422
LR  - 20191210
IS  - 1661-8157 (Print)
IS  - 1661-8157 (Linking)
VI  - 93
IP  - 47
DP  - 2004 Nov 17
TI  - [Reflux disease therapy].
PG  - 1963-9
AB  - The frequency of gastroesophageal reflux disease is on a constant rise in western 
      countries. Reflux therapy can be subdivided into the treatment of acute erosive 
      reflux esophagitis and the subsequent recurrence prophylaxis, and into the 
      treatment of non-erosive reflux disease as well as the atypical reflux symptoms. 
      Based on conventional large-scale studies, a highly effective therapy is 
      available which offers virtually complete acid blockade using proton pump 
      inhibitors (PPI) of the prazole type. Used for acute treatment, they offer a cure 
      for reflux esophagitis and freedom from symptoms in approx. 90% of the cases, 
      while also showing high efficacy in recurrence prophylaxis. Conversely, the rate 
      of side effects, particularly serious ones, is very low and the long-term safety 
      of this therapy has been good. Since the risk of erosive reflux esophagitis 
      recurring is > 80% without PPI therapy, the majority of the patients will require 
      a long-term, potentially even life-long therapy with PPI. Other therapeutic 
      options are being discussed as alternatives to such long-term prophylaxis. In 
      selected cases, surgical therapy by laparoscopic fundoplication is one option. 
      Alternatively, endoscopical anti-reflux procedures are increasingly coming into 
      use; their merit in long-term prophylaxis however, cannot yet be evaluated. 
      Whenever PPI therapy does not lead to complete freedom from symptoms, an 
      alternative therapeutic approach should be given consideration even in patients 
      with atypical reflux symptoms. The therapy of the Barrett's esophagus, a 
      potentially long-term sequelae of reflux disease, will not be dealt with in this 
      overview, as it is the subject of a separate presentation.
FAU - Allescher, H D
AU  - Allescher HD
AD  - Zentrum fur Innere Medizin, Gastroenterologie, Hepatologie und Stoffwechsel, 
      Klinikum Garmisch-Partenkirchen. hans.allescher@klinikum-gap.de
LA  - ger
PT  - Comparative Study
PT  - Journal Article
TT  - Refluxkrankheit--Therapie.
PL  - Switzerland
TA  - Praxis (Bern 1994)
JT  - Praxis
JID - 101468093
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Anti-Ulcer Agents/adverse effects/therapeutic use
MH  - Esophagitis, Peptic/*therapy
MH  - Esophagoscopy
MH  - Fundoplication
MH  - Gastroesophageal Reflux/*therapy
MH  - Hernia, Hiatal/therapy
MH  - Humans
MH  - Laparoscopy
MH  - Outcome and Process Assessment, Health Care
MH  - Proton Pump Inhibitors
MH  - Secondary Prevention
EDAT- 2005/01/20 09:00
MHDA- 2005/04/23 09:00
CRDT- 2005/01/20 09:00
PHST- 2005/01/20 09:00 [pubmed]
PHST- 2005/04/23 09:00 [medline]
PHST- 2005/01/20 09:00 [entrez]
AID - 10.1024/0369-8394.93.47.1963 [doi]
PST - ppublish
SO  - Praxis (Bern 1994). 2004 Nov 17;93(47):1963-9. doi: 10.1024/0369-8394.93.47.1963.